With the Wegovy pill live, the race is already on for what comes next: more oral GLP-1s, the amylin combo CagriSema, Lilly's orforglipron, and uses well beyond weight. A neutral map of the 2026 obesity-drug pipeline.
January 2026 outlooks pointed to a crowded obesity-drug pipeline: oral GLP-1s becoming a reality, the amylin-GLP-1 combination CagriSema filed for FDA review, Eli Lilly's oral orforglipron awaiting a decision, and GLP-1s expanding into new cardiometabolic indications.
With the oral Wegovy pill live, attention turned to what follows. Early-2026 forecasts described several fronts. First, oral therapy is no longer hypothetical — the once-daily Wegovy pill arrived in January, and Lilly's oral, non-peptide orforglipron was awaiting an FDA decision expected in 2026, potentially adding another convenient option.
Second, new mechanisms are advancing. CagriSema — a fixed-dose combination of the amylin analogue cagrilintide and semaglutide — was filed with the FDA in December 2025 and positioned as potentially the first once-weekly amylin-plus-GLP-1 combination for weight management; a regulatory decision was anticipated during 2026. Additional combinations and next-generation candidates were also in development.
Third, the use case is broadening. Forecasts noted GLP-1s expanding into new FDA-approved indications beyond weight and diabetes — areas such as cardiovascular risk reduction — reframing the class as cardiometabolic medicine. Direct-to-consumer access models were also expected to keep growing.
For consumers, a deeper pipeline means more options but also more complexity and more marketing noise. Pipeline status is fluid: filings, decision dates, and trial readouts shift, and "in development" or "filed" is not the same as "available." Treating these forecasts as a map of possibilities — to discuss with a qualified prescriber — rather than a shopping list keeps expectations grounded.